Tighter controls are needed to root out bogus patient groups

doi:10.1136/bmj.329.7478.1307-a

BMJ 2004;329:1307 (4 December), doi:10.1136/bmj.329.7478.1307-a

News roundup

Tighter controls are needed to root out bogus patient groups

London Zosia Kmietowicz

Patient organisations need to be more tightly regulated to protect the public from bogus groups and undue influence from the pharmaceutical industry and other funding bodies, MPs heard last week.

Setting standards on transparency and accountability would help to distinguish legitimate patient groups from those set up by drug companies to promote awareness of a specific condition and drugs to treat it, said witnesses at the fourth public hearing of the health committee�s inquiry into the influence of the pharmaceutical industry.

There are more than 200 national patient groups in the United Kingdom and many rely on funding from the pharmaceutical industry, especially if they are concerned with less emotional and more mundane matters which do not attract the public gaze, said Melinda Letts, chair of the committee of medicines working group on patient information.

"The answer is not to ban funding from the pharmaceutical industry but . . . [Full text of this article]

Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to StumbleUpon StumbleUpon Add to Technorati Technorati What's this?